A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT06109272 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

660

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Livmoniplimab
DRUG: Budigalimab
DRUG: Durvalumab
DRUG: Atezolizumab
DRUG: Bevacizumab
DRUG: Tremelimumab

Sponsor

AbbVie